Glioma Panel

What is Glioma Panel test?

Glioma Panel is a focused molecular test set that evaluates three cornerstone biomarkers in diffuse gliomas: 1p/19q codeletion, IDH1/2 mutations, and MGMT promoter methylation, to refine diagnosis, prognosis, and treatment planning in line with modern integrated classifications.

Why consider Glioma Panel test?

• Improves diagnostic accuracy beyond histology by distinguishing oligodendroglioma from astrocytoma and stratifying glioblastoma biology, which impacts prognosis and therapy choices.
• Provides predictive information: MGMT promoter methylation is associated with better response to alkylating chemotherapy (e.g., temozolomide), particularly relevant in high‑grade and elderly glioma settings.

Who should get tested for Glioma Panel test?

• Patients with newly diagnosed diffuse gliomas or glioblastoma where integrated histo‑molecular classification is needed to guide management and clinical trial eligibility.
• Patients with limited prior profiling or recurrent tumors where clarifying IDH status, confirming 1p/19q, and establishing MGMT methylation can influence second‑line strategies.

More Information about Glioma Panel test

OTHER NAMES: Glioma Core Molecular Panel, Glioma Marker Panel

Glioma is a primary tumor of glial cells in the brain and spinal cord, now classified primarily by molecular markers alongside histology, especially IDH mutation status and 1p/19q codeletion in adults. Modern classification separates adult diffuse gliomas into IDH‑mutant astrocytoma, IDH‑mutant and 1p/19q‑codeleted oligodendroglioma, and IDH‑wildtype glioblastoma, which differ in prognosis and therapy response.